Literature DB >> 8397249

IFN-gamma-induced recognition of the antigen-processing variant CMT.64 by cytolytic T cells can be replaced by sequential addition of beta 2 microglobulin and antigenic peptides.

W A Jefferies1, G Kolaitis, R Gabathuler.   

Abstract

The present study describes the functional nature of the MHC class I determinants expressed in CMT.64 cells and was undertaken to define and further analyze the deficiency in the cell line CMT.64 in the hope of elucidating the relative functional importance of constituent parameters in the recognition of these cells by CTL. We show that induction of Kb in CMT.64 cells with IFN-gamma results in molecules capable of presenting VSV epitopes to the appropriate CTL. However, cells untreated with IFN-gamma and infected with VSV are not recognized by VSV-specific CTL. This study reveals that beta 2 m3 is synthesized in limiting amounts in uninduced CMT.64 and becomes highly expressed after IFN-gamma induction. Thus, the limiting amount of beta 2 m expressed in uninduced cells may partially explain the inability of the cells to present viral components of CTL recognition. This concept is reinforced by the experiments identifying two functional effects upon the addition of immunogenic peptides to uninduced CMT.64 cells: at high peptide concentrations in excess of 5 nM, CMT.64 cells are recognized efficiently after 5 min of incubation; at the limiting peptide concentration of 500 pM, uninduced CMT.64 cells are only recognized providing beta 2m is added before or simultaneously with the antigenic peptide. BFA, an inhibitor of protein transport, and emetine, an inhibitor of protein synthesis, were used to show that at high peptide concentrations, 25 microM, recognition takes place after the peptide has stabilized the limited amount of newly arriving MHC/beta 2m complexes, devoid of peptides, at the cell surface of uninduced CMT.64 cells. These experiments thereby exclude the possibility that peptides are taken up into CMT.64 cells for assembly, transport and surface expression of functional MHC/beta 2m/peptide complexes. In summary, our data expands previous research showing the importance of exogenous beta 2m in sensitizing cells for CTL recognition with peptides added exogenously. These functional experiments also imply that the concentration of endogenous beta 2m may regulate the amount of MHC class I expressed at the cell surface and receptive to exogenous peptides. Finally, the phenotype of CMT.64 cells we describe provides evidence of the complexity of the Ag-presenting capacity of this cell line not previously identified in other studies on these cells, thus revising our understanding of the Ag-processing deficiency in these cells.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8397249

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

1.  MHC class I dysfunction of glioma stem cells escapes from CTL-mediated immune response via activation of Wnt/β-catenin signaling pathway.

Authors:  Wei Yang; Yanyan Li; Ruoling Gao; Zenghe Xiu; Ting Sun
Journal:  Oncogene       Date:  2019-10-07       Impact factor: 9.867

Review 2.  Therapeutic vaccination with tumor cells that engage CD137.

Authors:  Karl Erik Hellstrom; Ingegerd Hellstrom
Journal:  J Mol Med (Berl)       Date:  2003-02-08       Impact factor: 4.599

3.  Surrogate antigen processing mediated by TAP-dependent antigenic peptide secretion.

Authors:  R Gabathuler; J Alimonti; Q J Zhang; G Kolaitis; G Reid; W A Jefferies
Journal:  J Cell Biol       Date:  1998-01-12       Impact factor: 10.539

4.  Mesenchymal stem cell carriers enhance antitumor efficacy of oncolytic adenoviruses in an immunocompetent mouse model.

Authors:  Esther Rincón; Teresa Cejalvo; Deepak Kanojia; Arantzazu Alfranca; Miguel Ángel Rodríguez-Milla; Raul Andrés Gil Hoyos; Yu Han; Lingjiao Zhang; Ramón Alemany; Maciej S Lesniak; Javier García-Castro
Journal:  Oncotarget       Date:  2017-07-11

5.  Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies.

Authors:  Jeffrey Schlom; Sofia R Gameiro; Christine M Minnar; Paul L Chariou; Lucas A Horn; Kristin C Hicks; Claudia Palena
Journal:  J Immunother Cancer       Date:  2022-06       Impact factor: 12.469

6.  Comparison of cell lines deficient in antigen presentation reveals a functional role for TAP-1 alone in antigen processing.

Authors:  R Gabathuler; G Reid; G Kolaitis; J Driscoll; W A Jefferies
Journal:  J Exp Med       Date:  1994-10-01       Impact factor: 14.307

7.  Trogocytosis of MHC-I/peptide complexes derived from tumors and infected cells enhances dendritic cell cross-priming and promotes adaptive T cell responses.

Authors:  Qian-Jin Zhang; Xiao-Lin Li; David Wang; Xiao-Cong Huang; J Michael Mathis; Wei-Ming Duan; David Knight; Runhua Shi; Jonathan Glass; Dong-Qing Zhang; Lea Eisenbach; Wilfred A Jefferies
Journal:  PLoS One       Date:  2008-08-29       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.